The Alfred Berman Foundation for Medical Research Report issue

Foundation Phase 2 Phase 3

Organization Overview

First Clinical Trial
2011
NCT01300975
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Alfred Berman Foundation

Active Ingredients

Drugs in Phase 3 Trials (2)

miltefosine (impavido) (1 trial)

paromomycin (humatin) (1 trial)

Drugs in Phase 2 Trials (1)

antimony (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leishmaniasis (Phase 3)

Leishmaniasis, Cutaneous (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3